A Phase I / II Clinical Study Of Enadenotucirev Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.

Trial Profile

A Phase I / II Clinical Study Of Enadenotucirev Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Enadenotucirev (Primary) ; Paclitaxel
  • Indications Ovarian cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms OCTAVE
  • Sponsors PsiOxus Therapeutics
  • Most Recent Events

    • 08 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2018.
    • 08 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.
    • 07 Jun 2016 Interim results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top